Evidence mapPaperPMID 20739685Full record

ArticleDiabetes2010

Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes.

Aaron M Secrest, Dorothy J Becker, Sheryl F Kelsey, Ronald E Laporte, Trevor J Orchard

6 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Diabetes, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 138 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 4 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04133922 early_phase1withdrawnstarted 2019, after this paper: background citation

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Ran2019Enrolled0Registered outcomes5Posted comparisons0ConditionsInsulin Sensitivity/Resistance, Type 1 DiabetesArmsDextrose 20 % in Water, GLP-1, Insulin
Open the trial in the graph
NCT05478707 phase2recruitingstarted 2023, after this paper: background citation

Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Ran2023Enrolled47Registered outcomes5Posted comparisons0ConditionsDiabetes Mellitus, Type 1, Endothelial DysfunctionArmsDulaglutide, Placebo
Open the trial in the graph
NCT03926598 completednot on this mapstarted 2019, after this paper: background citation

User Evaluation of the Guide To Goals Application - a Care Coordination Tool to Translate ADA Clinical Standards of Care for Children With T2D Into Practice

TypeobservationalSponsorGeorgia Institute of TechnologyRan2019 to 2019Enrolled6ConditionsType2 Diabetes MellitusArmsPatient and/or Family Member Intervention, Certified Diabetes Educator Intervention, Physician Intervention, Front Desk Staff Intervention, Nurse Intervention
NCT04614623 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D

TypeinterventionalSponsorChildren's Hospital New Orleans, LARan2020 to 2022Enrolled120ConditionsType1diabetesArmsAHCL pump, Video conferencing Application
NCT05653518 narecruitingnot on this mapstarted 2023, after this paper: background citation

Using Closed-Loop Artificial Pancreas Technology to Reduce Glycemic Variability and Subsequently Improve Cardiovascular Health in Type 1 Diabetes

TypeinterventionalSponsorUniversity of VirginiaRan2023 to 2027Enrolled40ConditionsType 1 DiabetesArmsTandem t:slim X2 with Control-IQ Technology, Sensor augmented pump (SAP) therapy
NCT05790785 recruitingnot on this mapstarted 2024, after this paper: background citation

Understanding Vascular Complications in Children From Type 1 Diabetes Diagnosis

TypeobservationalSponsorUniversity of British ColumbiaRan2024 to 2027Enrolled150ConditionsType 1 Diabetes, Cardiovascular Complications, Child, Adolescent
3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 4 syntheses or guidelines pooled it, 356 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Hemostatic Effects of Exercise-related Hypoglycemia in Male Persons With Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2024
    Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Obesity in Adults with Type 1 Diabetes Mellitus.Journal of obesity & metabolic syndrome · 2026
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Life stage transitions for people with type 1 diabetes.The lancet. Diabetes & endocrinology · 2025
    Review
  20. Article

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Aaron M SecrestDepartment of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Dorothy J Becker
Sheryl F Kelsey
Ronald E Laporte
Trevor J Orchard
University of Pittsburgh · US

Funding

NIDDK NIH HHS F30 DK082137NIDDK NIH HHS F30-DK082137
6 · The paper itself

Abstract

objectiveLittle is known concerning the primary cause(s) of mortality in type 1 diabetes responsible for the excess mortality seen in this population. RESEARCH DESIGN AND

methodsThe Allegheny County (Pennsylvania) childhood-onset (age < 18 years) type 1 diabetes registry (n = 1,075) with diagnosis from 1965 to 1979 was used to explore patterns in cause-specific mortality. Cause of death was determined by a mortality classification committee of at least three physician epidemiologists, based on the death certificate and additional records surrounding the death.

resultsVital status for 1,043 (97%) participants was ascertained as of 1 January 2008, revealing 279 (26.0%) deaths overall (141 females and 138 males). Within the first 10 years after diagnosis, the leading cause of death was acute diabetes complications (73.6%), while during the next 10 years, deaths were nearly evenly attributed to acute (15%), cardiovascular (22%), renal (20%), or infectious (18%) causes. After 20 years' duration, chronic diabetes complications (cardiovascular, renal, or infectious) accounted for >70% of all deaths, with cardiovascular disease as the leading cause of death (40%). Women (P < 0.05) and African Americans (P < 0.001) have significantly higher diabetes-related mortality rates than men and Caucasians, respectively. Standardized mortality ratios (SMRs) for non-diabetes-related causes do not significantly differ from the general population (violent deaths: SMR 1.2, 95% CI 0.6-1.8; cancer: SMR 1.2, 0.5-2.0).

conclusionsThe excess mortality seen in type 1 diabetes is almost entirely related to diabetes and its comorbidities but varies by duration of diabetes and particularly affects women and African Americans.

Indexed as

AdolescentAge of OnsetBlack or African AmericanBlack PeopleCause of DeathChildCohort StudiesDiabetes ComplicationsDiabetes Mellitus, Type 1Diabetic AngiopathiesDiabetic NephropathiesFemaleHumansInfectionsMaleNeoplasms

Identifiers

PMID20739685
PMCPMC2992785
OpenAlexW2170938622

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.